Navigation Links
West Penn Allegheny Health System is First in Pennsylvania to Perform Groundbreaking Minimally-Invasive Procedure for Swallowing Disorder
Date:5/9/2013

Pittsburgh, PA (PRWEB) May 09, 2013

A multidisciplinary team of physicians and nurses from West Penn Allegheny Health System’s(WPAHS) Institute for the Treatment of Esophageal and Thoracic Disease is the first in Pennsylvania to offer per-oral endoscopic myotomy (POEM), an innovative, minimally-invasive surgical approach to treat the swallowing disorder called achalasia.

Achalasia is a problem that affects the ability of the esophagus to move food toward the stomach. Some symptoms include regurgitation of food and difficulty swallowing. The condition is caused by a malfunctioning lower esophageal sphincter (LES). When the LES fails to relax, patients have difficulty moving food past the muscle and into the stomach. In addition, the esophageal muscle fails to squeeze in a coordinated and effective fashion, thereby compounding the symptoms of obstruction.

“These patients can’t eat well- their food tends to get stuck in the esophagus,” said Abhijit Kulkarni, MD, director of the gastroenterology lab at Allegheny General Hospital and a leader within the newly created Institute for the Treatment of Esophageal and Thoracic Disease.

Medications exist to treat achalasia and physicians have used balloons to stretch the LES, but neither of those methods tends to yield good long-term results, Dr. Kulkarni said.

In one of the most successful surgical treatments for achalasia, Heller myotomy, the outer layer of the LES and esophageal muscle are cut so that the obstruction is relieved and food can move through the esophagus and into the stomach. Heller myotomy was first performed via open surgery through the chest or abdomen and has more recently been done through four to five small incisions in the abdomen.

POEM enables physicians to effectively treat achalasia in the same way but without making any incisions in the patient’s skin. Employing the NOTES philosophy (natural orifice translumenal endoscopic surgery), physicians use an endoscope to access the esophagus via the patient’s mouth.

Surgical instruments are passed through the endoscope and the myotomy is performed internally, without disruption to the skin.

“It’s a novel approach,” said Blair Jobe, MD, Director of the WPAHS Institute for the Treatment of Esophageal and Thoracic Disease. “By eliminating the need for external incisions, we are able to speed the healing process, limit or eliminate pain, and achieve a cosmetically flawless result. Our first patient went home within 24 hours of surgery, used no pain medication and noticed a dramatic improvement in his symptoms.”

Drs. Jobe and Kulkarni joined thoracic surgeon and Co-Director of the Institute, Lana Schumacher, MD, gastroenterologist Shyam Thakkar, MD, and Toshitaka Hoppo, MD, a general surgeon specializing in esophageal surgery, on the multidisciplinary team that performed the first POEM procedure at Canonsburg General Hospital. The procedure is currently being performed as part of a clinical trial to help doctors determine if it can be an effective treatment option for achalasia in the future. Physicians expect to enroll 15 patients in the study.

According to Dr. Schumacher, the likelihood of patients developing gastroesophageal reflux may be higher after the POEM procedure compared to laparoscopic Heller myotomy.

“That’s the primary reason for nesting this novel procedure into a clinical trial with well-defined outcome measures,” Dr. Schumacher said.

Other rare but serious risks involved with the study procedure include laceration or tear to the esophagus, postoperative bleeding and failed endoscopic procedure, requiring alternative treatment.

Achalasia affects about one in 100,000 people and its cause is poorly understood. WPAHS is one of a select few medical centers in the United States offering POEM surgery. WPAHS is currently enrolling patients ages18 to 80 with an established diagnosis of achalasia and no prior surgical intervention to treat it in the POEM study. Patients must meet additional criteria and pregnant women are not eligible. Patients will be followed in the study for approximately one year. There is no compensation for participation.

For more information on the POEM trial at West Penn Allegheny Health System, contact Katherine Nega at 412-578-1343 or knega(at)wpahs(dot)org.

The Institute for the Treatment of Esophageal and Thoracic Disease at WPAHS is a comprehensive, multi-disciplinary program that focuses on the treatment of patients with lung cancer, mediastinal diseases, esophageal cancer, Barrett’s esophagus, hiatal hernia, esophageal motility disorders, gastroesophageal reflux disease, and swallowing issues such as achalasia.

###

Read the full story at http://www.prweb.com/releases/2013/5/prweb10714773.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study by Allegheny General Hospital Physicians Shows Oral Immunotherapy is a Safe, Effective Alternative to Allergy Shots for Ragweed Sufferers
2. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Unlimited Support To Dieters, Making the Transfer to Long-term Improved Health Easier
3. Sherri Gastelum and Platinum Tax Defenders Offer 5 Tips on Understanding Health Care Tax Issues from the Affordable Care Act
4. Mobile health app developed at UCLA simplifies process of choosing birth control method
5. Fresh Healthy Vending Supports Houston City Council Nutritious Meal Program for After-School Activities
6. WomenHeart Wins “Full Circle Award” at the 4th M2W®-HW™ - The Marketing Health & Wellness to Women Conference
7. American Psychiatric Nurses Association Honors Psychiatric Mental Health Nurses for Delivering Quality & Innovative Care for National Nurses Week and Mental Health Month
8. Fast Food Hasnt Gotten Much Healthier, Study Says
9. Zane Benefits Publishes New Information on Defined Contribution Health Plans
10. Integrative Nutrition Donates Over $10,000 to Earth Day Network’s Healthy Schools Initiative
11. For adolescents, Subway food may not be much healthier than McDonalds, UCLA study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point to lead ... reduce waste, and support renewable energy. They believe this is a crucial part of ... solutions for health issues, and maintain that destroying the environment in the pursuit of ...
(Date:4/24/2017)... Antonio, TX (PRWEB) , ... April 24, 2017 , ... ... by the glitterati, those unreal icons inhabiting the rarified air of pop and film ... the paparazzi and anyone snapping pictures: the smile. Grins now run the gamut from ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the undisputed ... Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than 100 ... in the last 25 years. , Now, due to changes in the broadcast media ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP Nutrition®, ... supplements, announced its popular products are now available for purchase on StackedNutrition.com, a ... the use of premium natural ingredients in making all of its products. These ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... advisor within the telehealth industry, announces the company’s VideoMedicine mobile platform has launched ... providers. Available 24 hours a day, Quick Care provides patients with the option ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Ind. , April 20, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Care Conference at the InterContinental Hotel in ... Zimmer Biomet will present at 11:20 a.m. Eastern Time. ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: